Evaluation of a gamification and flipped-classroom program used in teacher training: Perception of learning and outcome | PLOS ONE
![Remote Sensing | Free Full-Text | UAV-Based Estimate of Snow Cover Dynamics: Optimizing Semi-Arid Forest Structure for Snow Persistence | HTML Remote Sensing | Free Full-Text | UAV-Based Estimate of Snow Cover Dynamics: Optimizing Semi-Arid Forest Structure for Snow Persistence | HTML](https://www.mdpi.com/remotesensing/remotesensing-13-01036/article_deploy/html/images/remotesensing-13-01036-g001.png)
Remote Sensing | Free Full-Text | UAV-Based Estimate of Snow Cover Dynamics: Optimizing Semi-Arid Forest Structure for Snow Persistence | HTML
![Effect of manual approaches with osteopathic modality on brain correlates of interoception: an fMRI study | Scientific Reports Effect of manual approaches with osteopathic modality on brain correlates of interoception: an fMRI study | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-020-60253-6/MediaObjects/41598_2020_60253_Fig1_HTML.png)
Effect of manual approaches with osteopathic modality on brain correlates of interoception: an fMRI study | Scientific Reports
![Frontiers | Baseline Volumetric T2 Relaxation Time Histogram Analysis: Can It Be Used to Predict the Response to Intravenous Methylprednisolone Therapy in Patients With Thyroid-Associated Ophthalmopathy? Frontiers | Baseline Volumetric T2 Relaxation Time Histogram Analysis: Can It Be Used to Predict the Response to Intravenous Methylprednisolone Therapy in Patients With Thyroid-Associated Ophthalmopathy?](https://www.frontiersin.org/files/Articles/614536/fendo-12-614536-HTML/image_m/fendo-12-614536-g001.jpg)
Frontiers | Baseline Volumetric T2 Relaxation Time Histogram Analysis: Can It Be Used to Predict the Response to Intravenous Methylprednisolone Therapy in Patients With Thyroid-Associated Ophthalmopathy?
![Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial - The Lancet Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial - The Lancet](https://www.thelancet.com/cms/attachment/64d9a26d-3ecc-4906-9193-5c38fd1297ee/gr1.gif)